CXR-LT 2024: A MICCAI challenge on long-tailed, multi-label, and zero-shot disease classification from chest X-ray

The CXR-LT series is a community-driven initiative designed to enhance lung disease classification using chest X-rays (CXR). It tackles challenges in open long-tailed lung disease classification and enhances the measurability of state-of-the-art techniques. The first event, CXR-LT 2023, aimed to achieve these goals by providing high-quality benchmark CXR data for model development and conducting comprehensive evaluations to identify ongoing issues impacting lung disease classification performance. Building on the success of CXR-LT 2023, the CXR-LT 2024 expands the dataset to 377,110 chest X-rays (CXRs) and 45 disease labels, including 19 new rare disease findings. It also introduces a new focus on zero-shot learning to address limitations identified in the previous event. Specifically, CXR-LT 2024 features three tasks: (i) long-tailed classification on a large, noisy test set, (ii) long-tailed classification on a manually annotated "gold standard" subset, and (iii) zero-shot generalization to five previously unseen disease findings. This paper provides an overview of CXR-LT 2024, detailing the data curation process and consolidating state-of-the-art solutions, including the use of multimodal models for rare disease detection, advanced generative approaches to handle noisy labels, and zero-shot learning strategies for unseen diseases. Additionally, the expanded dataset enhances disease coverage to better represent real-world clinical settings, offering a valuable resource for future research. By synthesizing the insights and innovations of participating teams, we aim to advance the development of clinically realistic and generalizable diagnostic models for chest radiography.

Novel AI-Based Quantification of Breast Arterial Calcification to Predict Cardiovascular Risk

Women are underdiagnosed and undertreated for cardiovascular disease. Automatic quantification of breast arterial calcification on screening mammography can identify women at risk for cardiovascular disease and enable earlier treatment and management of disease. In this retrospective study of 116,135 women from two healthcare systems, a transformer-based neural network quantified BAC severity (no BAC, mild, moderate, and severe) on screening mammograms. Outcomes included major adverse cardiovascular events (MACE) and all-cause mortality. BAC severity was independently associated with MACE after adjusting for cardiovascular risk factors, with increasing hazard ratios from mild (HR 1.18-1.22), moderate (HR 1.38-1.47), to severe BAC (HR 2.03-2.22) across datasets (all p<0.001). This association remained significant across all age groups, with even mild BAC indicating increased risk in women under 50. BAC remained an independent predictor when analyzed alongside ASCVD risk scores, showing significant associations with myocardial infarction, stroke, heart failure, and mortality (all p<0.005). Automated BAC quantification enables opportunistic cardiovascular risk assessment during routine mammography without additional radiation or cost. This approach provides value beyond traditional risk factors, particularly in younger women, offering potential for early CVD risk stratification in the millions of women undergoing annual mammography.